

Sixth Latin America Health Technology Assessment Policy Forum

2021 HTAi LATAM Policy Forum

**"Deliberative processes for informed decision-making by health technology assessment"**

**SURVEY OF THE SITUATION IN LATIN AMERICA**

During the month of September 2021, a brief survey was sent to some participants of the Policy Forum to investigate the current status of deliberative processes for informed decision-making by health technology assessment in the Latin American and Caribbean region.

It was mostly answered by heads of HTA agencies or government agencies responsible for the generation of coverage policies and benefit packages that affect a large portion of the population. We certainly thank all those who took the time to answer the questionnaire.

These preliminary results could support the discussions that will take place during the Policy Forum. Any comments or suggestions you may wish to make about these results are welcome. The objective is to be able to finalize the Policy Forum with a more complete and definite information to integrate into the report of the results of the Forum and the subsequent publication.



|  |  | **Argentina** | **Brazil** | **Colombia** | **Costa Rica**  | **Chile** | **Ecuador** | **El Salvador** | **Mexico** | **Paraguay** | **Peru** | **Uruguay**  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **STAGE of Identification and nomination of technologies to be evaluated**  |
|  | *Is there a formal and explicit process to engage different stakeholders in the* ***stage of identification and prioritization*** *of the* *technologies to be assessed?* |
|  |  | Yes | No | Yes | No | YES | No | Yes | No | No | No | Yes |  |
|  | **Regardless of the existence or lack of a formal process, the manner in which the following stakeholders are involved in the stage of identification and prioritization of those technologies to be assessed is as follows:** |
|  | Min. of Health and other public agencies | +++ | +++ | +++ | + | +++ | +++ | +++ | +++ | +++ | +++ | +++ |  |
|  | Drug and device manufacturers | + | - | - | - | - | - | - | - | ++ | - | +++ |  |
|  | Patients | +++ | - | + | - | - | + | - | - | ++ | - | +++ |  |
|  | Citizens/Users | + | - | + | - | - | - | - | - | - | - | +++ |  |
|  | Providers/hospitals  | + | - | + | - | - | ++ | +++ | +++ | ++ | +++ | +++ |  |
|  | Scientific societies/clinical experts | + | - | + | + | + | + | +++ | - | ++ | +++ | +++ |  |
|  | Payers  | +++ | - | ++ | - | + | ++ | - | +++ | +++ | +++ | +++ |  |
|  | Experts (in bioethics, economics, others)  | + | - | ++ | - | - | ++ | - | - | +++ | - | +++ |  |
|  | Representatives of the legislative or judicial branch  | + | - | - | - | - | - | - | - | +++ | - | +++ |  |
|  | **TECHNOLOGY ASSESSMENT** STAGE |
|  | *Is there a formal and explicit process to engage different stakeholders at the technology* ***assessment*** *stage?* |
|  |  | Yes | Yes | Yes | No | Yes | No | No | Yes | Yes | Yes | Yes |  |
|  | **Regardless of the existence or lack of a formal process, the manner in which the following stakeholders are involved in the technology assessment stage is as follows:** |
|  | Min. of Health and other public agencies | +++ | +++ | - | + | +++ | +++ | +++ | +++ | +++ | +++ | +++ |  |
|  | Drug and device manufacturers | ++ | ++ | - | - | + | - | - | + | ++ | - | ++ |  |
|  | Patients | +++ | ++ | + | - | + | - | - | + | ++ | - | ++ |  |
|  | Citizens/Users | + | ++ | + | - | + | - | - | + | - | - | ++ |  |
|  | Providers/hospitals  | ++ | ++ | - | - | ++ | ++ | +++ | +++ | ++ | +++ | ++ |  |
|  | Scientific societies/clinical experts | +++ | ++ | +++ | + | + | + | +++ | + | ++ | +++ | +++ |  |
|  | Payers  | +++ | ++ | - | - | + | ++ | +++ | +++ | +++ | - | +++ |  |
|  | Experts (in bioethics, economics, others)  | ++ | ++ | +++ | - | + | ++ | - | + | +++ | - | +++ |  |
|  | Representatives of the legislative or judicial branch  | - | + | - | - | + | - | - | + | +++ | - | ++ |  |
|  | **Recommendation and/or decision making STAGE** |
|  | *Is there a formal and explicit process to engage different stakeholders in the stage* ***of issuing recommendations and/or decision-making*** *on the technologies?* |
|  |  | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Yes |  |
|  | **Regardless of the existence or lack of a formal process, the way in which the following stakeholders are involved in the stage of recommendation and / or decision making on technologies is as follows:** |
|  | Min. of Health and other public agencies | +++ | +++ | - | + | +++ | +++ | +++ | +++ | +++ | +++ | +++ |  |
|  | Drug and device industry | - | - | - | - | + | - | - | + | ++ | - | + |  |
|  | Patients | + | - | - | - | +++ | - | - | + | ++ | - | + |  |
|  | Citizens/Users | - | - | - | - | +++ | - | - | + | - | - | + |  |
|  | Providers/hospitals  | + | - | - | - | +++ | ++ | +++ | +++ | ++ | +++ | + |  |
|  | Scientific societies/clinical experts | + | - | +++ | - | +++ | + | +++ | + | ++ | +++ | ++ |  |
|  | Payers  | +++ | - | - | - | +++ | ++ | +++ | +++ | +++ | +++ | ++ |  |
|  | Experts (in bioethics, economics, others)  | - | - | +++ | - | +++ | ++ | - | + | +++ | - | ++ |  |
|  | Representatives of the legislative or judicial branch  | - | - | - | - | ++ | - | - | + | +++ | - | + |  |
|  | ***Was there a deliberative process involved in defining the governance, structure and characteristics of the HTA process and decision-making in the health system?*** |
|  |  | Yes | Yes | Yes | No | Yes | Unknown | Unknown | Yes | Yes | Unknown | Yes |  |
|  | ***How are stakeholders chosen to participate in deliberative processes?*** |
|  | Open to all (public call) |  |  | ✓ |  |  |  |  |  |  |  |  |  |
|  | Open to all who qualify (application process) |  |  |  |  | ✓ |  |  |  |  |  |  |  |
|  | Nominated by relevant stakeholders (nomination process) | ✓ |  |  |  | ✓ |  |  |  |  | ✓ |  |  |
|  | By invitation or appointment only (closed procedure) | ✓ |  |  |  |  |  | ✓ |  |  | ✓ |  |  |
|  | A combination of these methods  |  | ✓ |  |  |  |  |  | ✓ | ✓ |  | ✓ |  |
|  | ***How are stakeholders’ perspectives represented?*** |
|  | Each participant provides their own views |  |  |  |  |  |  |  |  |  |  | ✓ |  |
|  | Each participant represents other people’s views (delegates) |  |  |  |  | ✓ |  |  |  |  | ✓ |  |  |
|  | Participants represent others, but are free to express their individual opinions as they see fit (trustees) | ✓ | ✓ |  |  |  |  |  |  |  |  |  |  |
|  | A combination of any of the above  |  |  | ✓ |  |  |  | ✓ | ✓ | ✓ |  |  |  |
|  | ***What is the deliberation like?*** |
|  | Open to the public  |  | ✓ | ✓ |  |  |  |  | ✓ |  |  |  |  |
|  | Closed to the public |  |  |  |  |  |  |  |  |  | ✓ |  |  |
|  | Open only to selected individuals or groups | ✓ |  |  |  | ✓ |  | ✓ | ✓ | ✓ |  | ✓ |  |
|  | ***What are the characteristics of the information that is made available to the deliberative process?*** |
|  | All information is made available to the HTA agency |  | ✓ |  |  | ✓ | ✓ |  |  | ✓ | ✓ |  |  |
|  | The information is summarized according to explicit methods | ✓ |  |  |  | ✓ | ✓ |  | ✓ | ✓ | ✓ | ✓ |  |
|  | The information is summarized without an explicit method |  |  |  | ✓ |  |  | ✓ | ✓ |  |  |  |  |
|  | ***What are the characteristics of the results of the deliberative process?*** |
|  | A non-binding recommendation is issued | ✓ | ✓ |  | ✓ |  |  |  | ✓ |  | ✓ |  |  |
|  | A binding recommendation is issued |  |  |  |  | ✓ |  |  | ✓ | ✓ |  |  |  |
|  | An opinion is given  |  |  |  |  |  |  |  |  | ✓ |  | ✓ |  |
|  | Other  |  |  |  |  |  | ✓ |  |  |  |  |  |  |
|  | ***How are the results of the deliberative process communicated?*** |
|  | In general, without targeting specific groups of stakeholders | ✓ | ✓ |  | ✓ | ✓ |  |  | ✓ |  |  | ✓ |  |
|  | Closely, targeting specific groups of stakeholders |  |  |  |  |  | ✓ | ✓ |  | ✓ | ✓ |  |  |
|  | They are not reported |  |  |  |  |  |  |  |  |  |  |  |  |
|  | ***How are the results of the deliberative process reconsidered?*** |
|  | Through additional deliberation |  |  |  |  |  |  |  |  |  |  |  |  |
|  | By appealing such result  | ✓ |  |  |  | ✓ |  |  |  |  |  |  |  |
|  | A combination of the above  |  |  |  |  |  |  | ✓ | ✓ |  |  | ✓ |  |
|  | They are not reconsidered |  | ✓ | ✓ |  |  | ✓ |  |  |  | ✓ |  |  |

**Interpretation of results:**

**+++: They have full voting and speaking privileges in a deliberative process;** **++: They actively participate in a deliberative process, but are only allowed to speak;**

**+ They can voice their opinions/ or be otherwise involved, though without an active participation in a deliberative process**

**-: They do not usually participate in this stage of the HTA process**

**Analyzed aspects and other comments regarding each country:** *Argentina:*  Aspect analyzed: National HTA AGENCY, the portion of the population of the country included in the health system and the HTA process that is being considered is approximately 76-100% Comments: Regulatory agencies and those generating coverage regulations participate in the deliberative processes with a right to vote. *Brazil:* Aspect analyzed: National HTA AGENCY, the portion of the country's population included in the health system and the HTA process under consideration is approximately 76-100%. Comments: The Conitec Plenary is not only composed of representations from all the Ministry of Health Secretariats, but also from the Federal Council of Medicine, the National Health Council, the National Health Surveillance Agency, the National Council of Health Secretaries, the National Council of Municipal Health Secretariats, and the National Supplementary Health Agency. *Colombia:* Aspect analyzed: National HTA Agency; the portion of the country's population included in the health system and the HTA process under consideration is approximately 76-100%. Comments: The experts consulted are the participants of the HTA Agency (IETS). In Colombia, public consultations are held to collect comments, though not deliberation, from stakeholders. C*osta Rica:* Aspect analyzed: National HTA AGENCY; the portion of the population of the country included in the health system and the HTA process that is being considered is approximately 76-100%. *Chile:*  Aspect analyzed: Ricarte Soto Law and National Cancer Law, the portion of the country's population included in the health system and the HTA process that is being considered is approximately 76-100%. *Ecuador:* Aspect analyzed: Public health system, the portion of the country's population included in the health system and ETESA process that is being considered is approximately 76-100%. Comments: In Ecuador, authorization to acquire the evaluated health technology can be granted or denied. *El Salvador:*  Aspect analyzed: Health service providers, the proportion of the country's population included in the health system and ETESA process that is being considered is approximately 76-100%. *Mexico:* Aspect analyzed: National HTA Agency, the portion of the country's population included in the health system and ETESA process that is being considered is approximately 76-100%. Comments: in Mexico, the HTA is carried out almost exclusively by government agencies (Ministry of Health and other public agencies) that are at the same time providers and payers of health services, and who participate in all stages of the HTA. The participation of other stakeholders varies according to the different stages of the HTA. *Paraguay:* Aspect analyzed: Ministry of health; the portion of the country's population included in the health system and the HTA process that is being considered is approximately 76-100%. *Peru:* Aspect analyzed: Ministry of health, the portion of the country's population included in the health system and the HTA process that is being considered is approximately 51-75%. Comments: In the case of COVID-19 vaccines, other institutions in the executive branch participated as well, such as the Ministry of Foreign Affairs, the Ministry of Economy, CONCYTEC (National Council of Science and Technology). *Uruguay:* Aspect analyzed: National HTA Agency, the portion of the country's population included in the health system and the HTA process that is being considered is approximately 76-100%.